HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a price target of $13. The reaffirmation of the Buy rating and price target suggests a positive outlook for the company's stock.

December 27, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reaffirmed a Buy rating on Coherus BioSciences with a $13 price target, indicating a positive outlook for the stock.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices in the short term. The reiteration of a Buy rating and a price target that suggests upside potential from the current market price is likely to be viewed positively by investors, potentially leading to a short-term increase in CHRS stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100